BTK and B-cell chronic lymphocytic leukemia: To date, drugs against phosphoinositide 3-kinase (PI3K) (idelalisib, duvelisib, copanlisib, umbralisib) and Bruton ́s Tyrosine Kinase (BTK) (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib) have been studied, and some approved, for the therapy of patients with CLL with excellent results, not only in progression free survival but also in overall survival, in comparison to standard chemoimmunotherapy (8).